Comparing 3D and 2D MRI techniques for assessing liver cirrhosis and portal hypertension
Three-dimensional MR Elastography and Two-dimensional MR Elastography for Assessing Cirrhosis and Portal Hypertension：A Prospective Multicenter Study
This study is testing whether a new 3D MRI technique can better predict liver pressure issues in people with cirrhosis compared to the standard 2D MRI method.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Shengjing Hospital Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT06205992 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of three-dimensional magnetic resonance elastography (3D-MRE) compared to two-dimensional magnetic resonance elastography (2D-MRE) in predicting hepatic venous pressure gradient (HVPG) in patients with cirrhosis. The study focuses on developing a non-invasive and accurate method for risk stratification and management of portal hypertension, which is a significant complication of cirrhosis. By analyzing the viscoelastic properties of liver tissue, the researchers hope to establish a reliable prediction system that could improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with confirmed cirrhosis who can undergo both 3D-MRE and 2D-MRE imaging.
Not a fit: Patients with liver cancer, acute portal hypertension, or those who have undergone liver or spleen surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method for better risk assessment and management of portal hypertension in patients with cirrhosis.
How similar studies have performed: Previous studies have shown promise with 2D-MRE in assessing liver conditions, but the use of 3D-MRE in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. age \> 18 years old 2. confirmed cirrhosis (laboratory, imaging and clinical symptoms) 3. with 3D-MRE and 2D-MRE within 1 month prior to HVPG measurement 4. written informed consent Exclusion Criteria: 1. any previous liver or spleen surgery 2. liver cancer; chronic acute liver failure 3. acute portal hypertension 4. unreliable HVPG, 3D-MRE or 2D-MRE results due to technical reasons 5. with liver interventional therapy between HVPG and MRE
Where this trial is running
Shenyang, Liaoning
- Shengjing Hospital of China Medical University — Shenyang, Liaoning, China (Recruiting)
Study contacts
- Study coordinator: Yu Shi
- Email: 18940259980@163.com
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.